IL17A and pancreatic neoplasm: Compared to healthy individuals, pancreatic cancer patients have remarkably higher serum levels of IL-17, and PDAC development and metastasis may be impacted by increasing levels of circulating Th17 cells and serum IL-17A [91,92].